These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 35545027)

  • 21. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
    Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promises and challenges of mucosal COVID-19 vaccines.
    Rathore APS; St John AL
    Vaccine; 2023 Jun; 41(27):4042-4049. PubMed ID: 37045682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CCR2 Signaling Restricts SARS-CoV-2 Infection.
    Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS
    mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives.
    Boechat JL; Chora I; Morais A; Delgado L
    Pulmonology; 2021; 27(5):423-437. PubMed ID: 33867315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 Pandemic.
    Moorlag SJCFM; Taks E; Ten Doesschate T; van der Vaart TW; Janssen AB; Müller L; Ostermann P; Dijkstra H; Lemmers H; Simonetti E; Mazur M; Schaal H; Ter Heine R; van de Veerdonk FL; Bleeker-Rovers CP; van Crevel R; Ten Oever J; de Jonge MI; Bonten MJ; van Werkhoven CH; Netea MG
    Clin Infect Dis; 2022 Aug; 75(1):e938-e946. PubMed ID: 35247264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCG vaccination provides protection against IAV but not SARS-CoV-2.
    Kaufmann E; Khan N; Tran KA; Ulndreaj A; Pernet E; Fontes G; Lupien A; Desmeules P; McIntosh F; Abow A; Moorlag SJCFM; Debisarun P; Mossman K; Banerjee A; Karo-Atar D; Sadeghi M; Mubareka S; Vinh DC; King IL; Robbins CS; Behr MA; Netea MG; Joubert P; Divangahi M
    Cell Rep; 2022 Mar; 38(10):110502. PubMed ID: 35235831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breakthrough infection evokes the nasopharyngeal innate immune responses established by SARS-CoV-2-inactivated vaccine.
    He X; Cao Y; Lu Y; Qi F; Wang H; Liao X; Xu G; Yang B; Ma J; Li D; Tang X; Zhang Z
    Front Immunol; 2023; 14():1181121. PubMed ID: 37457721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience.
    Pilapitiya D; Wheatley AK; Tan HX
    EBioMedicine; 2023 Jun; 92():104585. PubMed ID: 37146404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.
    Gralinski LE; Sheahan TP; Morrison TE; Menachery VD; Jensen K; Leist SR; Whitmore A; Heise MT; Baric RS
    mBio; 2018 Oct; 9(5):. PubMed ID: 30301856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired immunity against SARS-CoV-2 infection and vaccination.
    Renia L; Ng LF
    EMBO Mol Med; 2023 Dec; 15(12):e16345. PubMed ID: 37966373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge.
    Sun S; Li E; Zhao G; Tang J; Zuo Q; Cai L; Xu C; Sui C; Ou Y; Liu C; Li H; Ding Y; Li C; Lu D; Zhang W; Luo P; Cheng P; Gao Y; Tu C; Pitard B; Rosenecker J; Wang B; Liu Y; Zou Q; Guan S
    Biomaterials; 2023 Jan; 292():121907. PubMed ID: 36436305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
    Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
    Front Immunol; 2020; 11():1979. PubMed ID: 32973803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
    Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intertwined Dysregulation of Ribosomal Proteins and Immune Response Delineates SARS-CoV-2 Vaccination Breakthroughs.
    Maurya R; Shamim U; Mishra P; Swaminathan A; Raina A; Tarai B; Budhiraja S; Pandey R
    Microbiol Spectr; 2023 Jun; 11(3):e0429222. PubMed ID: 37022180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response.
    Chen L; Zhang H; Li M; Wu B; Zhang Z; Gong R
    Front Immunol; 2022; 13():1005321. PubMed ID: 36466882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.
    Mitsi E; Diniz MO; Reiné J; Collins AM; Robinson RE; Hyder-Wright A; Farrar M; Liatsikos K; Hamilton J; Onyema O; Urban BC; Solórzano C; Belij-Rammerstorfer S; Sheehan E; Lambe T; Draper SJ; Weiskopf D; Sette A; Maini MK; Ferreira DM
    Nat Commun; 2023 Oct; 14(1):6815. PubMed ID: 37884506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
    Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
    Front Immunol; 2021; 12():772240. PubMed ID: 34858430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies.
    Varghese PM; Tsolaki AG; Yasmin H; Shastri A; Ferluga J; Vatish M; Madan T; Kishore U
    Immunobiology; 2020 Nov; 225(6):152008. PubMed ID: 33130519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model.
    Cameron MJ; Kelvin AA; Leon AJ; Cameron CM; Ran L; Xu L; Chu YK; Danesh A; Fang Y; Li Q; Anderson A; Couch RC; Paquette SG; Fomukong NG; Kistner O; Lauchart M; Rowe T; Harrod KS; Jonsson CB; Kelvin DJ
    PLoS One; 2012; 7(9):e45842. PubMed ID: 23029269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.